Orally, once daily, preferably in the morning at least 15 minutes before food.

Lercanidipine works by blocking calcium channels in vascular smooth muscle, leading to vasodilation and reduction in peripheral vascular resistance. Enalapril inhibits the angiotensin-converting enzyme (ACE), which prevents the conversion of angiotensin I to angiotensin II (a potent vasoconstrictor) and reduces aldosterone secretion, leading to vasodilation, reduced sodium and water retention, and decreased blood pressure.

• •Hypersensitivity to Lercanidipine, Enalapril, or any other ACE inhibitor or dihydropyridine derivative.
• •Pregnancy (especially 2nd and 3rd trimesters) and lactation.
• •History of angioedema related to previous ACE inhibitor therapy.
• •Hereditary or idiopathic angioedema.
• •Severe renal impairment (creatinine clearance <30 mL/min).
• •Severe hepatic impairment.
• •Left ventricular outflow tract obstruction (e.g., severe aortic stenosis).
• •Unstable angina pectoris or recent (within 1 month) myocardial infarction.
• •Concomitant use with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m²).

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Symptoms of overdose include marked hypotension, bradycardia, reflex tachycardia, dizziness, palpitations, renal failure, and severe peripheral vasodilation with possible prolonged systemic hypotension. Management involves symptomatic and supportive treatment, including intravenous fluid administration, vasopressors, and close monitoring of vital signs. Hemodialysis can remove enalaprilat from the circulation.

Veridipin Plus is contraindicated during pregnancy due to the risk of fetal harm from Enalapril, especially in the 2nd and 3rd trimesters. It is also not recommended during lactation, as both active substances are excreted into breast milk.